Skip to content
Medical Health Aged Care

Trial shows saliva is on par with blood tests for managing epilepsy through keto diet

Monash University 2 mins read

A simple saliva test could transform the lives of millions of children and adults worldwide who are on the keto diet to manage their epilepsy, and who currently endure uncomfortable finger prick tests.  

 

Monash researchers, in collaboration with China’s Shenzhen Children’s Hospital and the global biotech firm MX3 Diagnostics, found that MX3’s handheld test was comparable in accuracy to existing blood tests. Urine and breath testing are also less invasive, but much less accurate. 

 

The device, called the MX3 LAB, utilises a test strip to non-invasively measure salivary levels of ketones - acids that are released when the body burns fat instead of carbohydrates for energy. 

 

People living with epilepsy and other conditions – especially children with drug-resistant epilepsy – are often prescribed the ketogenic diet, which has been proven to reduce seizures. Knowing their ketone levels allows them to adjust the composition and timing of their food intake to help further reduce symptoms. 

 

Joint first author Dr Neha Kaul, a neuroscience researcher at Monash University’s School of Translational Medicine, said the test would be a game changer for parents, especially of younger children. 

 

“All that’s needed is for the tongue to touch the test strip for just a few seconds, and you can see the results in 30 seconds, without having to endure a painful finger prick test,” Dr Kaul said. “Being able to manage not only your kids’ diet but also eliminate some of the discomfort of living with the condition is going to really help.” 

 

“Parents could administer the test in the morning and use the information for their menu planning the same day.”

 

The study was published in the journal Epilepsia. Blood and saliva samples from some 40 children (with a median age of four and a half years) were taken on day one and day seven of a week-long admission to the SCH to start ketogenic diet therapy for the first time. The researchers found that the results correlated with ketone levels in the blood. 

 

MX3 CEO Michael Luther said, “Nobody likes to give blood. Even a finger prick can be painful, especially when done every day. The breakthrough biomarker testing system that the MX3 team has developed will significantly improve quality of life for these brave kids who are really just interested in leading a normal, pain-free life.” 

 

Further research is needed to determine whether the test has similar accuracy in infants, and its accuracy for people who have been on the ketogenic diet for a prolonged period. 

 

The project was undertaken as part of a larger collaborative program, the Shenzhen Sanming Project, with Professor Ingrid Scheffer from The University of Melbourne, and other researchers.

 

The clinical benefits of the test are now being validated in a telehealth clinical trial conducted by Monash University through Alfred Health, via a Medical Research Future Fund (MRFF) grant, which will conclude in 2027

- ENDS -

MEDIA ENQUIRIES 

Helena Powell

Media Advisor (medical), Monash University 

M: +61 474 444 171

E: [email protected] 

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: [email protected]

For more Monash media stories, visit our news and events site 

 

About MX3

MX3 Diagnostics is a digital health company based in Austin, TX and Melbourne, Australia. MX3 has developed an advanced biomarker testing system that uses saliva and sweat to provide real-time personalized diagnostics and health insights. Our clinically validated testing solutions and cloud analytics are deployed by over 600 elite sports teams, Fortune 1000 companies, government agencies, and healthcare facilities around the world.

More from this category

  • Medical Health Aged Care
  • 17/06/2026
  • 12:09
Royal Australian College of GPs

SA GPs call for patient-centred care as abortion bill to be put to vote [re-issue]

This media release was first issued on 3 June 2026, as:SA GPs call for patient-centred care as new abortion bill flagged The Royal Australian College of GPs (RACGP) has expressed strong concern regarding a proposed abortion bill expected to be introduced to the South Australian Parliament in early June. RACGP SA Deputy Chair Dr Clare Keogh said decisions about pregnancy must remain between a person and their healthcare team, not politicians. “Abortion care is healthcare. These are deeply personal decisions that should be made by individuals in consultation with their GP and trusted health professionals,” she said. “We are concerned…

  • Contains:
  • Medical Health Aged Care
  • 17/06/2026
  • 06:15
Monash University

New Guiding Principles to improve incontinence medication safety for people living with dementia

Monash University researchers are today launching the first co-designed resources to safely guide the use of urinary incontinence medications for people living with dementia. Doctors routinely prescribe medications to manage urinary incontinence, but the medications can carry hidden dangers for people with dementia, increasing the risk of side effects such as worsening memory loss. Despite the risks, the healthcare sector previously lacked evidence-based co-designed resources to help families and healthcare professionals decide when to start or stop treatment. Dr Amanda Cross, who developed the 10 Guiding Principles with her team from the Centre for Medicine Use and Safety at the…

  • Medical Health Aged Care
  • 16/06/2026
  • 22:47
Optimi Health Corp.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber SchemeVANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.